Andrew Williams

发表

Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression.

J. Chin, J. Lewis, A. Zijlstra, 2014, Cancer research.

Progression upon Clustering and Is a Clinical Indicator of Prostate Cancer Integrin-Free Tetraspanin CD 151 Can Inhibit Tumor Cell Motility

J. Chin, J. Lewis, A. Zijlstra, 2013 .

Molecular and Cellular Pathobiology Integrin-Free Tetraspanin CD 151 Can Inhibit Tumor Cell Motility uponClustering and Is aClinical Indicator of Prostate Cancer Progression

J. Chin, J. Lewis, A. Zijlstra, 2013 .

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

J. Chin, V. Chalasani, C. Martínez, 2011, Expert opinion on biological therapy.

Ghrelin receptor as a novel imaging target for prostatic neoplasms

J. Lewis, L. Luyt, R. Nesbitt, 2012, The Prostate.

Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma.

P. Black, F. Saad, J. Chin, 2013, Urologic oncology.

Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b).

J. Chin, G. Bauman, A. Autrán-Gómez, 2012, The Journal of urology.

High-intensity focused ultrasound: where are we and where to from here?

J. Chin, V. Chalasani, C. Martínez, 2010, Expert review of anticancer therapy.

Cumulative summation graphs are a useful tool for monitoring positive surgical margin rates in robot‐assisted radical prostatectomy

L. Stitt, S. Pautler, J. Izawa, 2011, BJU international.

A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years.

A. Westenberg, P. Gilling, C. Frampton, 2006, European urology.

Primary mucinous cystadenocarcinoma of the pelvic retroperitoneum in a male.

J. Chin, C. Martínez, S. Boyle, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Cost analysis of two follow-up strategies for localized kidney cancer: a Canadian cohort comparison.

S. Pautler, L. Nott, Marie Dion, 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer.

J. Chin, G. Bauman, A. Arifin, 2016, The Journal of urology.

Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer.

J. Chin, S. Pautler, C. Martínez, 2011, European urology.

Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer.

J. Chin, M. Billia, K. Siddiqui, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Role of PCA3 test in clinical decision making for prostate cancer diagnosis

J. Chin, G. Hidas, D. Pode, 2015 .

How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?

J. Chin, L. Stitt, S. Pautler, 2011, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

High-intensity focused ultrasound: where are we and where to from here?

J. Chin, V. Chalasani, Andrew Williams, 2010, Expert review of anticancer therapy.

Histological changes in the human prostate after radiotherapy and salvage high intensity focused ultrasound.

J. Chin, K. Kwan, V. Chalasani, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.